ArticleScientific reports2025
Integrative analysis of scRNA-seq and RNA-seq to investigate the prognostic value of lactylation and fibroblast-related genes in intrahepatic cholangiocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Intrahepatic cholangiocarcinoma (ICCA), the second most prevalent primary liver cancer, is linked to a poor prognosis. However, the role of histone lactylation-related epigenetic modifications in ICCA remains poorly understood. This study aimed to identify reliable prognostic biomarkers and establish a foundation for targeted therapies. Specifically, this study integrated single-cell RNA sequencing (scRNA-seq), bulk transcriptomic data from TCGA-ICCA and GSE107943, and a curated list of histone lactylation-related genes. Cell–cell communication analysis revealed a significant CXCL12–CXCR4 interaction between apCAFs and vCAFs (p < 0.01). Prognostic markers were identified through regression models, and a risk signature was developed and validated using ROC curves. Five genes—STMN1, UBE2T, CENPF, C5orf34, and FAM72C—were established as prognostic indicators. FAM72C exhibited a negative correlation with plasmacytoid dendritic cells (cor = − 0.355), while CENPF correlated negatively with mast cells (cor = − 0.386) (p < 0.05). Drug sensitivity analysis revealed that the IC50 values of 10 candidate compounds, including AZD6482, BX.798, and Bicalutamide, exhibited significant differences between the two groups (p < 0.05). RT-qPCR confirmed the overexpression of STMN1, UBE2T, CENPF, and FAM72C in ICCA tissues. Overall, this study highlights the significance of histone lactylation-associated prognostic genes and potential therapeutic targets in ICCA, providing insights into tumor microenvironment modulation and precision treatment approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.